News

Chugai and Gero Enter into Joint Research and License Agreement to Develop Novel Therapies for Age-Related Diseases

Chugai Files for Additional Tumor-Agnostic Indication of Alecensa for ALK Fusion / Rearrangement Gene-Positive Solid Tumors Including Pediatric Patients

Eli Lilly’s Announcement Regarding Oral GLP-1 Orforglipron (Results of Phase III ACHIEVE-1 for Type 2 Diabetes Published in The New England Journal of Medicine)

Phase I/II Study in Hemophilia A Suggests NXT007 May Have the Potential to Provide Hemostatic Normalization

Roche Announces Global Phase III SUNMO Study Data for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Combination Therapy with Lunsumio and Polivy)

Roche Announces New Safety Information of Elevidys for Non-Ambulatory Duchenne Muscular Dystrophy

Galderma’s Announcement Regarding NEMLUVIO (New Long Term Data Presentation in Atopic Dermatitis)

Verastem Oncology’s Announcement Regarding AVMAPKI (Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma)

Positive Results from Phase III TALENTACE Study of Tecentriq and Avastin for Unresectable Hepatocellular Carcinoma

Chugai Obtains First Regulatory Approval in Japan for Vabysmo for Additional Indication of Angioid Streaks, a Cause of Vision Loss

PiaSky Approved in Taiwan as First Subcutaneous Treatment for Paroxysmal Nocturnal Hemoglobinuria

Chugai Files for Additional Indication of Tecentriq for the Treatment of Thymic Carcinoma

Chugai Receives Regulatory Approval for “ELEVIDYS” as a Gene Therapy Product for Duchenne Muscular Dystrophy in Japan

Roche Announces New Ten-Year Data of Perjeta-Based Regimen for HER2-Positive Early Breast Cancer

Verastem Oncology’s Announcement Regarding AVMAPKI (FDA Approval for AVMAPKI FAKZYNJA Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer)

Chugai Announces 2025 1^st Quarter Results

Personnel Changes

F. Hoffmann-La Roche Announces First Quarter Sales 2025

Eli Lilly’s Announcement Regarding Oral GLP-1 Orforglipron (Statistically Significant Efficacy and a Safety Profile Consistent with Injectable GLP-1 Medicines in Phase III ACHIEVE-1 for Type 2 Diabetes)

First Positive Phase III Results Presented at Japanese Ophthalmological Society Meeting Demonstrated that Vabysmo Sufficiently Improved Vision in Japanese Patients with Angioid Streaks

Roche’s Announcement Regarding Trontinemab (Presentation of Latest Data in Alzheimer’s Disease at AD/PD)

Relief Efforts Support for the Earthquake in Myanmar

Joint Research Results on Regulatory T cells between Osaka University Immunology Frontier Research Center and Chugai Published in Nature

Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan

Position and Policy Regarding Reduction of the Investment Unit

Chugai Obtains Regulatory Approval for First Tablet for SMA, Evrysdi

Anti-CD20 Monoclonal Antibody Rituxan^® Approved for Treatment of Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Childhood That Has not yet Become Intractable

Chugai Selected as a “Nadeshiko Brand”

Chugai Launches “LUNSUMIO for Intravenous Infusion,” a Bispecific Antibody for Relapsed or Refractory Follicular Lymphoma in Japan

Chugai Selected as “KENKO Investment for Health” for the Second Consecutive Year

Chugai Marks 100th Anniversary of Its Founding

Chugai Obtains Regulatory Approval for Tecentriq for the Additional Indication of Alveolar Soft Part Sarcoma, an Ultra-rare Disease

Awarded "Human Capital Leaders 2024" and "Human Capital Management Quality 2024 (Gold)" in the "Human Capital Survey 2024"

Galderma’s Announcement Regarding NEMLUVIO (EC Approval for the Treatment of Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis)

Chugai Announces Consolidated 2024 Full Year Results and Forecasts for 2025

Notice of Distribution of Retained Earnings

Chugai and GSK Sign Collaboration Agreement for Anti-Dengue Virus Antibody AID351

Organizational and Personnel Changes

Chugai, SoftBank Corp., and SB Intuitions Sign Memorandum of Understanding for Joint Research Aimed at Innovating Clinical Development Processes and Accelerating New Drug Development through Generative AI - Aiming to Create Advanced Services in the Pharmaceutical and Healthcare Industry -

F. Hoffmann-La Roche Announces Financial Results for Fiscal 2024

Roche Announces New Results from EMBARK Study of Elevidys in Duchenne Muscular Dystrophy

Chugai Wins the MHLW Minister’s Award at the Seventh Japan Medical Research and Development Grand Prize for the Discovery of an ALK-Positive Lung Cancer Treatment “Alecensa”

Transfer and Future Marketing of Anti-Cancer Agent “Tarceva^® Tablets 25, 100 and 150” in Japan

Introduction of a New Human Resources Management System

Verastem Oncology’s Announcement Regarding Avutometinib (FDA Acceptance and Priority Review of New Drug Application for Avutometinib (in Combination with Defactinib) for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer)